Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - fondaparinux sodium - injection, solution - 5.0 mg - fondaparinux sodium 5.0 mg/0.4 ml

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - fondaparinux sodium - injection, solution - 7.5 mg - fondaparinux sodium 7.5 mg/0.6 ml

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 5 mg in 0.4 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.2) and use in specific populations (8.6).] - active major bleeding. - bacterial endocarditis. - thrombocytopenia associated with a positive in vitro test for anti-platelet antib

United States - English - NLM (National Library of Medicine)

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with arixtra during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - fondaparinux (fondaparinux sodium) - solution for injection - 5mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - fondaparinux (fondaparinux sodium) - solution for injection - 5mg/ml